MENLO PARK, California, January 13, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), the main developer of high-quality, extremely delicate sequencing options, celebrates long-read sequencing, at present referred to as Nature Strategies. “Method of the Year 2022.” Nature Strategies had seen the impression of lengthy learn sequencing in a number of groundbreaking research, together with these utilizing PacBio expertise from the Vertebrate Genome Challenge, Telomere-to-Telomere Consortium, and Human Pangeome Reference Consortium, amongst others.
“PacBio has pioneered genomic transformation by making long-read sequencing extra correct and accessible than ever earlier than with the introduction of HiFi sequencing,” he mentioned. Christian Henry, President and Chief Govt Officer of PacBio. “Nature Strategies It acknowledges the significance of extremely correct lengthy learn sequencing to proceed advancing genomic analysis. We consider our prospects’ use of the high-throughput Revio system, which we anticipate to be obtainable within the first quarter of 2023, will end in a dramatic improve in the usage of long-read sequencing to energy new research.”
Using the identical extremely delicate HiFi chemistry as PacBio’s Sequel instrument collection, the Revio system is designed to offer 20kb+ sequencing reads with >99.9% accuracy, uniform protection, distinctive software efficiency for variant calling and splicing, and DNA methylation detection.
Nature Strategies cited 4 wish-list gadgets that may learn the sequence longer: decrease price, larger accuracy, time financial savings, and elevated implementation profit. We consider the Revio system will fulfill that want listing by providing increased accuracy, higher economic system, increased pace, and elevated manufacturing capability, together with the flexibility to deal with large-scale genomics tasks that had been as soon as thought of impractical with present applied sciences available on the market. The Revio system is designed to permit PacBio prospects to do extra science and sequence as much as 1,300 full human genomes per 12 months in a single system. $1000 {dollars} per genome.
For extra on the way forward for lengthy studying rating, try: Nature Methods news feature Pay attention and take heed to insights from key genomics thought leaders Nature Strategies editor vivien marxInterview with PacBio Co-Founder and Chief Scientist Jonas KorlachPhD on the evolution and persevering with significance of lengthy studying sequencing and the continued collaboration with our prospects on PacBio’s podcast Conversations with Scientists.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a number one life science expertise firm that designs, develops and manufactures superior sequencing options to assist scientists and medical researchers clear up genetically complicated issues. Our merchandise and expertise in growth stem from two very completely different core applied sciences centered on accuracy, high quality and completeness, which embrace our present HiFi lengthy learn sequencing and our rising SBB™ quick learn sequencing applied sciences. Our merchandise are for options in a variety of analysis functions, together with human germline sequencing, plant and animal sciences, infectious illness and microbiology, oncology and different rising functions. For extra info please go to www.pacb.com and comply with @PacBio.
PacBio merchandise are supplied for Analysis Use Solely. Not to be used in diagnostic procedures.
forward-looking statements
This press launch accommodates “forward-looking statements” inside the which means of Part 21E of the Securities Change Act of 1934 and the USA Non-public Securities Litigation Reform Act of 1995, as amended. All statements aside from statements of historic truth are forward-looking. statements, together with statements concerning: the long run availability, use, accuracy, benefits, high quality or efficiency of PacBio merchandise or applied sciences, together with the Revio rating system, or the advantages or anticipated advantages of use; prospects’ capacity to scale HiFi rankings by the usage of Revio; yield, accuracy, affordability, protection, run instances, information, density, price per genome, pricing, and variety of genomes sequenced per 12 months; enhancements in effectivity and accuracy; anticipated supply time and different future occasions. Readers are cautioned to not place undue reliance on these forward-looking statements, and such forward-looking statements are absolutely certified by reference to the next warning statements. All forward-looking statements are legitimate solely as of the date of this press launch and are based mostly on present expectations and contain a variety of assumptions, dangers and uncertainties that might trigger precise outcomes to vary materially from such forward-looking statements. others, the inherent difficulties of creating, manufacturing, launching, advertising and promoting new merchandise and producing anticipated new gross sales; assumptions, dangers and uncertainties concerning the flexibility to draw new prospects and retain and improve gross sales from current prospects; potential product efficiency and high quality points and doable delays in commercialization timelines; quickly altering applied sciences and intense competitors in genomic sequencing that may make the merchandise PacBio is creating outdated or out of competitors; provide chain dangers; efficiently full the event of a product that’s not but commercially obtainable; prospects and potential prospects who prohibit or droop actions utilizing our merchandise; The impression of US export restrictions on shipments of PacBio merchandise to sure international locations; and third social gathering claims that declare infringement of patents and proprietary rights or try to void PacBio’s patents or proprietary rights. Readers are strongly inspired to learn the total warning statements in PacBio’s filings with the Securities and Change Fee, together with the dangers outlined on the corporate’s Varieties 8-Okay, 10-Okay, and 10-Q. PacBio disclaims any obligation to replace or revise any forward-looking statements.
Individuals
Traders:
Todd Friedman
650,521.8450
[email protected]
media:
Lizelda Lopez
[email protected]
SOURCE Pacific Biosciences CaliforniaInch.
#PacBio #Celebrates #Natures #Strategies #Calling #LongTerm #Sequencing #Methodology #Yr
